Fujirebio Diagnostics, Inc. Email Format
Biotechnology ResearchTokio, Japan501-1000 Employees
Fujirebio is a world leading in vitro diagnostics (IVD) company and innovation-driven content provider, enabling breakthrough diagnostic solutions to reach patients worldwide through science, partnership, and proven global impact. Founded in Tokyo in 1950, Fujirebio has spent more than 75 years developing pioneering biomarkers and diagnostic technologies across oncology, infectious diseases, and neurological disorders. Today, our technology plays a vital role in many of the world’s most trusted IVD tests – often reaching patients through partnerships with leading diagnostic companies operating across multiple platforms. Our open business model is built on a virtuous circle: we invest more than 15% of our base revenue in R&D to develop novel diagnostic content; we prove its value through real-world validation on our own Lumipulse® platform and through our connection with SRL, one of the world’s largest clinical laboratories; and we share proven solutions globally through our Contract Development and Manufacturing Organization (CDMO) services. Revenues from these partnerships are reinvested to fuel further innovation. We are particularly active in neurological diagnostics. Our FDA-cleared Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio test represents a significant advance in accessible blood-based Alzheimer’s disease diagnostics, and our 2022 acquisition of ADx NeuroSciences further strengthened our neurological biomarker pipeline. Fujirebio is a consolidated subsidiary of H.U. Group Holdings, Inc. (Tokyo Stock Exchange: TYO 4544), employing more than 1,200 people across Japan, Europe, and the Americas.
1-888-653-2347 
support@leadiq.com 
